Table 3. Response to Treatment with XC-302 among 21 Patients with relapsed or Refractory Non-Hodgkin's Lymphoma.

Response	XC-302 dose, BID			All (n = 21), n
	25 mg (n = 3), n	37.5 mg (n = 9), n	50 mg (n = 7*), n
Overall response rate	0	0	2	2
Complete response	0	0	0	0
Partial response	0	0	1	1
Minor response	0	0	1	1
Stable disease	3	1	2	6
Progressive disease	0	8	3	11

^*Two patients lost to follow-up during the study are not included in this analysis.